No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $54
BofA Securities analyst Jason Gerberry maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler analyst Edward Tenthoff maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $62.According to TipRanks data, the analyst has a success
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Veeva Systems (VEEV) and Arrowhead Pharmaceuticals (ARWR)